• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

    2/24/25 8:00:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XERS alert in real time by email

    Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire

    Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, Xeris' CEO.

    "We are pleased to have Anh return to Xeris as our first Chief Medical Officer. Anh is an accomplished clinician-scientist and biopharma executive dedicated to driving advancements in regulatory strategy, clinical development, medical affairs, and commercial launches," said John Shannon, CEO of Xeris. "He brings his forward-thinking leadership to Xeris at a time when we prepare to embark in our Phase 3 development of XP-8121 and continue to drive growth of our commercial portfolio, especially Recorlev®."

    Mr. Shannon continued, "We are fortunate that Ken has strategically played an active role in finding his successor and has graciously agreed to help and support in the transition of his organization under the new leadership of Anh. Ken's guidance and support will undoubtedly ensure a smooth passing of the baton and set the stage for continued success of the entire Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions."

    Dr. Nguyen brings an extensive wealth of clinical and leadership experience to his role as CMO, leading the development of first-in-class therapies including circular RNA-based oncology treatments, gene-edited xenotransplants, immuno-oncology vaccines, and allogeneic CAR-T therapies. Dr. Nguyen served as Vice President and Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio), where he directed the IND clearance and early-phase clinical trials of AAV gene therapies for neuromuscular rare disease. Among his many achievements, Dr. Nguyen shaped clinical and regulatory policies for breakthrough therapies while serving as a medical officer at the NIH, FDA, and CMS. During his Robert Wood Johnson Foundation Health Policy Fellowship serving on the US Senate HELP Committee, Dr. Nguyen was a key contributor to the landmark "21st Century Cures Act". He also led the establishment of an ambulatory surgical service to expedite pediatric orphan disease and oncology trials, earning the prestigious NIH Director's Award. During his tenure at Xeris, Dr. Nguyen served as the program medical lead for Gvoke®'s NDA and MAA approvals and multiple IND clearances for endocrine and rare disease, including novel endocrine drug co-formulations for diabetes, immunology, and pediatric epilepsy. Dr. Nguyen received an MBA from University of Chicago, a MD from Rutgers New Jersey Medical School, and completed his residency and fellowship training in anesthesiology and cardiovascular anesthesia at Massachusetts General Hospital, Harvard Medical School.

    "It has been an honor to be part of an exceptionally talented team and a privilege to help lead Xeris through its evolution to a commercial-stage biopharmaceutical company," said Ken Johnson. "I'm very proud of what we have accomplished and am confident that Dr. Nguyen will lead Xeris to new levels of success."

    "I'm excited to help lead the scientific efforts at Xeris, to collaborate and usher a new era of transformative therapies that leverage our innovation and strategic partnerships, to redefine patient care," said Dr. Nguyen.

    About Xeris

    Xeris (NASDAQ:XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners.

    Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

    Forward-Looking Statements

    Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development of its product portfolio vision and strategy for its internal functions, the potential growth of its commercial portfolio, and other statements containing the words "will," "would," "continue," "expect," "should," "anticipate" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators' ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250224024050/en/

    Investor Contact

    Allison Wey

    Senior Vice President, Investor Relations and Corporate Communications

    [email protected]

    Get the next $XERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XERS

    DatePrice TargetRatingAnalyst
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    3/28/2024$5.00Outperform
    Oppenheimer
    8/28/2023$4.50Buy
    Craig Hallum
    10/21/2022$4.00Buy
    Jefferies
    4/28/2022$6.50Buy
    Craig Hallum
    2/16/2022$8.00 → $6.00Outperform
    SVB Leerink
    12/31/2021$6.00 → $8.00Outperform
    SVB Leerink
    12/31/2021$4.25 → $5.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/13/24 4:15:08 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/12/24 6:28:50 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schmid John P. bought $10,314 worth of shares (5,400 units at $1.91) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      5/10/24 4:04:26 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services

    $XERS
    Financials

    Live finance-specific insights

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

      Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou

      3/6/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 5:17:37 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xeris Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 4:34:36 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      1/26/24 4:23:46 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

      Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X

      2/24/25 8:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Announces CEO Succession Plan

      John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20

      7/8/24 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Xeris Biopharma Holdings Inc.

      10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 4:12:34 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 7:22:16 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xeris Biopharma Holdings Inc.

      DEFA14A - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      4/23/25 5:02:10 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Xeris Biopharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

      11/11/24 7:52:12 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Xeris Biopharma with a new price target

      Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00

      3/28/24 7:52:34 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Xeris Biopharma with a new price target

      Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50

      8/28/23 7:53:14 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Mcculloch Kevin covered exercise/tax liability with 733 shares, decreasing direct ownership by 0.04% to 1,683,585 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      4/3/25 4:20:05 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brady James Aloysius was granted 100,000 shares (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:45:00 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Brady James Aloysius

      3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:44:04 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care